Cargando…

Review article: new treatments for advanced differentiated thyroid cancers and potential mechanisms of drug resistance

The treatment of advanced, radioiodine refractory, differentiated thyroid cancers (RR-DTCs) has undergone major advancements in the last decade, causing a paradigm shift in the management and prognosis of these patients. Better understanding of the molecular drivers of tumorigenesis and access to ne...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hamidi, Sarah, Hofmann, Marie-Claude, Iyer, Priyanka C., Cabanillas, Maria E., Hu, Mimi I., Busaidy, Naifa L., Dadu, Ramona
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10331470/ https://www.ncbi.nlm.nih.gov/pubmed/37435488 http://dx.doi.org/10.3389/fendo.2023.1176731

Ejemplares similares

Recent advances and emerging therapies in anaplastic thyroid carcinoma
por: Cabanillas, Maria E., et al.
Publicado: (2018)

Differentiated Thyroid Cancer: Management of Patients with Radioiodine Nonresponsive Disease
por: Busaidy, Naifa Lamki, et al.
Publicado: (2012)

Neoadjuvant selpercatinib for advanced medullary thyroid cancer
por: Jozaghi, Yelda, et al.
Publicado: (2020)

Challenges Associated with Tyrosine Kinase Inhibitor Therapy for Metastatic Thyroid Cancer
por: Cabanillas, Maria E., et al.
Publicado: (2011)

OR27-6 Combination Vemurafenib (BRAF Inhibitor)/Cobimetinib (MEK Inhibitor)/Atezolizumab (Anti-PDL1 Inhibitor) in BRAF-V600E Mutated Anaplastic Thyroid Cancer (ATC): Initial Safety and Feasibility
por: Cabanillas, Maria, et al.
Publicado: (2019)

Circulating BRAF V600E Cell-Free DNA as a Biomarker in the Management of Anaplastic Thyroid Carcinoma
por: Iyer, Priyanka C., et al.
Publicado: (2018)

Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma
por: Iyer, Priyanka C., et al.
Publicado: (2018)

MON-554 Brain Metastases in Thyroid Cancer: Molecular Profile and Institutional Experience of a Single Tertiary Referral Center in the Era of Kinase Inhibitor Therapy
por: Agosto Salgado, Sarimar, et al.
Publicado: (2019)

Immune checkpoint inhibitor related hypophysitis: diagnostic criteria and recovery patterns
por: Nguyen, Ha, et al.
Publicado: (2021)

MON-491 TRK-Fusion Thyroid Cancer: A Clinical Overview in a Large Population at a Single Cancer Center
por: Fazeli, Sasan, et al.
Publicado: (2020)

Impact of Somatic Mutations on Survival Outcomes in Patients With Anaplastic Thyroid Carcinoma
por: Wang, Jennifer Rui, et al.
Publicado: (2022)

PSAT385 Single Center Experience with the Combination of Lenvatinib and Pembrolizumab for the Treatment of Anaplastic Thyroid Cancer
por: Vodopivec, Danica M, et al.
Publicado: (2022)

MON-LB015 Sporadic MTC in Children: Characterization of a Rare Disease
por: Gammons, Sarah, et al.
Publicado: (2020)

Novel Therapeutics in Radioactive Iodine-Resistant Thyroid Cancer
por: Fullmer, Tanner, et al.
Publicado: (2021)

Complete Surgical Resection Following Neoadjuvant Dabrafenib Plus Trametinib in BRAF(V600E)-Mutated Anaplastic Thyroid Carcinoma
por: Wang, Jennifer R., et al.
Publicado: (2019)

Pulmonary cavitation in patients with thyroid cancer receiving antiangiogenic agents
por: Datar, Saumil, et al.
Publicado: (2020)

Surgery After BRAF-Directed Therapy Is Associated with Improved Survival in BRAF(V600E) Mutant Anaplastic Thyroid Cancer: A Single-Center Retrospective Cohort Study
por: Zhao, Xiao, et al.
Publicado: (2023)

Updates on the Management of Advanced, Metastatic, and Radioiodine Refractory Differentiated Thyroid Cancer
por: Tumino, Dario, et al.
Publicado: (2017)

Anaplastic transformation in thyroid cancer revealed by single-cell transcriptomics
por: Lu, Lina, et al.
Publicado: (2023)

Larotrectinib Before Initial Radioactive Iodine Therapy in Pediatric TRK Fusion–Positive Papillary Thyroid Carcinoma: Time to Reconsider the Treatment Paradigm for Distantly Metastatic Disease?
por: Waguespack, Steven G., et al.
Publicado: (2022)

Differentiated Thyroid Cancer, From Active Surveillance to Advanced Therapy: Toward a Personalized Medicine
por: Matrone, Antonio, et al.
Publicado: (2020)

Theranostic Options for Radioiodine-Refractory Differentiated Thyroid Carcinoma: Recent Advances, Challenges, and Road Ahead
por: Satapathy, Swayamjeet, et al.
Publicado: (2022)

Surgical Decision-Making in Thyroiditis: A Review Article
por: Alnefaie, Sahar M
Publicado: (2023)

RAC1 Alterations Induce Acquired Dabrafenib Resistance in Association with Anaplastic Transformation in a Papillary Thyroid Cancer Patient
por: Bagheri-Yarmand, Rozita, et al.
Publicado: (2021)

New Therapies for Advanced Thyroid Cancer
por: Laha, Diprajan, et al.
Publicado: (2020)

Radiomics-based ultrasound models for thyroid nodule differentiation in Hashimoto’s thyroiditis
por: Fang, Mengyuan, et al.
Publicado: (2023)

MON-LB097 The Genomic Landscape of Preoperative FNAs Positive for the Afirma GSC Medullary Thyroid Cancer Classifier
por: Waguespack, Steven, et al.
Publicado: (2019)

Case Report: A New Entity: Multiple Differentiated Variant of Papillary Thyroid Carcinoma With Advanced Clinical Behavior
por: Yang, Jing, et al.
Publicado: (2021)

Utility of Antibodies in the Diagnoses of Thyroid Diseases: A Review Article
por: Gupta, Amit K, et al.
Publicado: (2022)

Editorial: Targeted therapy in advanced thyroid cancer
por: Boucai, Laura
Publicado: (2022)

Thyroid nodules: need for a universal risk stratification system
por: Majety, Priyanka
Publicado: (2023)

Poorly Differentiated Thyroid Carcinoma: An Incubating Entity
por: Sadow, Peter M., et al.
Publicado: (2012)

Female Reproductive Factors and Differentiated Thyroid Cancer
por: Moleti, Mariacarla, et al.
Publicado: (2017)

Molecular Predictors for Advanced Papillary Thyroid Carcinoma Recurrence
por: de Castro, Taciana Padilha, et al.
Publicado: (2019)

Vitamin D, FOXO3a, and Sirtuin1 in Hashimoto's Thyroiditis and Differentiated Thyroid Cancer
por: Roehlen, Natascha, et al.
Publicado: (2018)

Transiently impaired endothelial function during thyroid hormone withdrawal in differentiated thyroid cancer patients
por: Hou, Li-ying, et al.
Publicado: (2023)

Feasibility of Apatinib in Radioiodine-Refractory Differentiated Thyroid Carcinoma
por: Du, Wei, et al.
Publicado: (2022)

Editorial: New strategies in treatment of differentiated thyroid carcinoma
por: Carrillo, Jose Federico, et al.
Publicado: (2022)

Thyroid Hormone Supplementation Therapy for Differentiated Thyroid Cancer After Lobectomy: 5 Years of Follow-Up
por: Kim, Soo Young, et al.
Publicado: (2020)

Pharmacodynamic Response to Anti-thyroid Drugs in Graves' Hyperthyroidism
por: Abbara, Ali, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_1cabp800jr3tck7bp9d2ogbilq